View Older Stories View More Recent Stories
-
Bausch Health Announces Early Exchange Offer Results for Exchange Offers
-
Bausch Health's Solta Medical acquires China distributor Shibo Group
-
Bausch Health's Aesthetics Business, Solta Medical, Acquires Longtime Distribution Partner, the Shibo Group, to Strengthen Presence in China
-
Bausch Health launches $1.6 billion debt exchange offer
-
Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes
-
Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference
-
Bausch + Lomb sets three-year growth targets at investor day
-
Bausch Health expands OraPharma dental unit to Canada and Puerto Rico
-
Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease
-
Bausch Health Co. Inc. (BHC) Misses Q3 EPS by 56c
-
Bausch Health Announces Third Quarter 2025 Results
-
Bausch Health Announces Results of Special Meeting of Shareholders
-
Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
-
Bausch Health to Announce Third Quarter 2025 Results on October 29
-
Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry
-
Bausch Health completes $63 million DURECT acquisition
-
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
-
Solta Medical reaches 5 million Thermage skin treatments milestone
-
Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System
-
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
-
Bausch Health expands CABTREO acne treatment to Quebec, Saskatchewan plans
-
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan
-
Paulson Capital increases Bausch Health stake to 19% after Icahn exit
-
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
-
Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners
-
Bausch Health Co. Inc. (BHC) Tops Q2 EPS by 36c
-
Bausch Health Co. Inc. (BHC) Misses Q2 EPS by 54c, provides guidance
-
Bausch Health Announces Second Quarter 2025 Results
-
Bausch Health to acquire DURECT for $63 million upfront
-
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
-
Bausch Health to reduce debt by $900 million using cash on hand
-
Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand
-
Bausch Health adds two pharmaceutical executives to board
-
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
-
CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans o
-
Bausch Health names Steven Lee as chief accounting officer
-
Bausch Health Appoints New Chief Accounting Officer
-
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two
-
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopa
-
Bausch Health to Announce Second Quarter 2025 Results on July 30
-
Bausch Health Announces 2025 Annual Meeting of Shareholder Results
-
Truist Lays Out Prelim Thoughts on Impact to Generic Drugs Amid WH Update on Drug Pricing
-
Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization
-
Bausch Health Companies (BHC) PT Lowered to $8 at Raymond James
-
Bausch Health Announces First Quarter 2025 Results
-
Bausch Health Co. Inc. (BHC) nnounces Health Canada Clearance of Solta Medical's Thermage FLX System
-
Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System
-
Bausch Health Co. Inc. (BHC) Announces Launch of Solta Medical's Fraxel FTX
-
Bausch Health Announces Launch of Solta Medical's Fraxel FTX(TM)
-
Bausch Health Co. Inc. (BHC) Says Icahn Has Economic Interest Covering Approximately 34% of Outstanding Shares
